0000000000243937

AUTHOR

Christian Rust

showing 12 related works from this author

Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis

2018

ObjectivePrimary sclerosing cholangitis (PSC) is a genetically complex, inflammatory bile duct disease of largely unknown aetiology often leading to liver transplantation or death. Little is known about the genetic contribution to the severity and progression of PSC. The aim of this study is to identify genetic variants associated with PSC disease progression and development of complications.DesignWe collected standardised PSC subphenotypes in a large cohort of 3402 patients with PSC. After quality control, we combined 130 422 single nucleotide polymorphisms of all patients—obtained using the Illumina immunochip—with their disease subphenotypes. Using logistic regression and Cox proportiona…

Male0301 basic medicineOncologyCandidate geneCholangitismedicine.medical_treatmentMedizinTrasplantament hepàticGenome-wide association studyKaplan-Meier EstimateLIVER FIBROSISLiver transplantationBioinformaticsSclerosingOral and gastrointestinalPrimary sclerosing cholangitis; genetics; liver transplantationCohort StudiesACTIVATION0302 clinical medicineMED/12 - GASTROENTEROLOGIAMULTIPLE2.1 Biological and endogenous factorsEPIDEMIOLOGYgeneticsAetiologyCIRRHOSISliver transplantationBilious diseases and biliousnessPrimary sclerosing cholangitisLiver Diseasedigestive oral and skin physiologyGastroenterologySingle NucleotidePrimary sclerosing cholangitiMiddle Aged3. Good healthULCERATIVE-COLITISDisease ProgressionFemale030211 gastroenterology & hepatologyAdultmedicine.medical_specialtyCholangitis SclerosingChronic Liver Disease and CirrhosisClinical SciencesMalalties del tracte biliarSingle-nucleotide polymorphismHEPATIC STELLATE CELLSPolymorphism Single NucleotideInternational PSC Study GroupArticlePrimary sclerosing cholangitisPaediatrics and Reproductive Medicine03 medical and health sciencesRare DiseasesClinical ResearchInternal medicineGeneticsmedicineHumansPolymorphismGENOME-WIDE ASSOCIATIONAlleleDigestive Diseases - (Gallbladder)Survival analysisProportional Hazards ModelsMALIGNANCYThe UK PSC ConsortiumTransplantationGastroenterology & Hepatologybusiness.industryProportional hazards modelmedicine.diseaseRISK LOCILogistic Models030104 developmental biology3121 General medicine internal medicine and other clinical medicinegeneticHepatic transplantationThrombospondinsDigestive DiseasesbusinessGenèticaGut
researchProduct

Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis

2013

To access publisher's full text version of this article click on the hyperlink at the bottom of the page Primary sclerosing cholangitis (PSC) is a severe liver disease of unknown etiology leading to fibrotic destruction of the bile ducts and ultimately to the need for liver transplantation. We compared 3,789 PSC cases of European ancestry to 25,079 population controls across 130,422 SNPs genotyped using the Immunochip. We identified 12 genome-wide significant associations outside the human leukocyte antigen (HLA) complex, 9 of which were new, increasing the number of known PSC risk loci to 16. Despite comorbidity with inflammatory bowel disease (IBD) in 72% of the cases, 6 of the 12 loci sh…

Linkage disequilibriumHISTONE DEACETYLASEGenotyping Techniquesendocrine system diseasesGenome-wide association studyDiseaseBioinformaticsLinkage Disequilibrium0302 clinical medicineGene FrequencyRisk FactorsOligonucleotide Array Sequence Analysis0303 health sciencesCrohn's diseaseeducation.field_of_studydigestive oral and skin physiologyCELIAC-DISEASEGenetic PleiotropyLifrarsjúkdómar3. Good healthFALSE DISCOVERY RATEULCERATIVE-COLITISgenetic association studydisease genetics030211 gastroenterology & hepatologySUSCEPTIBILITY LOCIPopulationCholangitis SclerosingSingle-nucleotide polymorphismHuman leukocyte antigenGENETIC RISKBiologyliverPolymorphism Single Nucleotidedigestive systemArticlePrimary sclerosing cholangitis03 medical and health sciencesFUNCTIONAL SIMILARITYGeneticsmedicineHumansGENOME-WIDE ASSOCIATIONeducation030304 developmental biologyNATURAL-HISTORYArfgengimedicine.diseasedigestive system diseasesimmunogeneticsGenetic LociCase-Control StudiesImmunologyGenome-Wide Association StudyINFLAMMATORY-BOWEL-DISEASE
researchProduct

102 NOVEL SUSCEPTIBILITY LOCI FOR PRIMARY SCLEROSING CHOLANGITIS IDENTIFIED BY GENOME-WIDE ASSOCIATION AND REPLICATION ANALYSIS

2011

GeneticsHepatologyReplication (statistics)medicineSusceptibility locusGenome-wide association studyBiologymedicine.diseasePrimary sclerosing cholangitisJournal of Hepatology
researchProduct

Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2…

2019

Norursodeoxycholic acid is an orally administered side chain-shortened homologue of ursodeoxycholic acid that undergoes hepatic enrichment with hepatoprotective, anti-inflammatory, and antifibrotic activity. We assessed the efficacy of two doses of norursodeoxycholic acid versus placebo for the treatment of non-alcoholic fatty liver disease.We did a multicentre, double-blind, placebo-controlled, randomised, phase 2 dose-finding clinical trial in tertiary referral hospitals and medical centres in Austria (n=6) and Germany (n=23) for patients with non-alcoholic fatty liver disease with or without diabetes. Patients with a clinical diagnosis of non-alcoholic fatty liver disease and serum alani…

AdultBlood GlucoseMalemedicine.medical_specialtyCholagogues and CholereticsPopulationPlaceboGastroenterologylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialDouble-Blind MethodlawNon-alcoholic Fatty Liver DiseaseDiabetes mellitusInternal medicinemedicineHumansAspartate Aminotransferaseseducationeducation.field_of_studyHepatologyDose-Response Relationship Drugbusiness.industryFatty liverUrsodeoxycholic AcidGastroenterologyAlanine TransaminaseMiddle Agedmedicine.diseaseLipidsUrsodeoxycholic acidClinical trialDose–response relationshipTreatment Outcome030220 oncology & carcinogenesis030211 gastroenterology & hepatologyFemalebusinessmedicine.drugThe lancet. Gastroenterologyhepatology
researchProduct

Mutational Characterization of the Bile Acid Receptor TGR5 in Primary Sclerosing Cholangitis

2010

Background: TGR5, the G protein-coupled bile acid receptor 1 (GPBAR1), has been linked to inflammatory pathways as well as bile homeostasis, and could therefore be involved in primary sclerosing cholangitis (PSC) a chronic inflammatory bile duct disease. We aimed to extensively investigate TGR5 sequence variation in PSC, as well as functionally characterize detected variants.Methodology/Principal Findings: Complete resequencing of TGR5 was performed in 267 PSC patients and 274 healthy controls. Six nonsynonymous mutations were identified in addition to 16 other novel single-nucleotide polymorphisms. To investigate the impact from the nonsynonymous variants on TGR5, we created a receptor mod…

Nonsynonymous substitutionMaleModels MolecularCandidate geneLinkage disequilibriumProtein ConformationDNA Mutational Analysislcsh:MedicineGenome-wide association studySUSCEPTIBILITYMULTIPLE SEQUENCE ALIGNMENTSReceptors G-Protein-CoupledMice0302 clinical medicineChildlcsh:ScienceGenetics and Genomics/Genetics of DiseaseGENE-EXPRESSIONGenetics0303 health sciencesMultidisciplinaryGastroenterology and Hepatology/Biliary TractCROHN-DISEASEMiddle AgedG protein-coupled bile acid receptor3. Good healthGenetics and Genomics/Gene FunctionULCERATIVE-COLITISChromosomes Human Pair 2WEB SERVER030211 gastroenterology & hepatologyFemaleResearch ArticleAdultAdolescentCholangitis SclerosingSingle-nucleotide polymorphismLocus (genetics)BiologyGenetics and Genomics/Complex TraitsPrimary sclerosing cholangitis03 medical and health sciencesYoung AdultDogsPROTEIN-COUPLED RECEPTORSLIVER-DISEASEmedicineAnimalsHumansAmino Acid SequenceBOWEL-DISEASE030304 developmental biologyAgedGastroenterology and Hepatology/Inflammatory Bowel DiseaseCYSTIC-FIBROSISlcsh:Rmedicine.diseaseGene Expression RegulationMutationCancer researchCattleColitis Ulcerativelcsh:Q
researchProduct

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 tria…

2019

© 2019 Elsevier Ltd. All rights reserved.

MaleBiopsyClinical Trial Phase IIIAdministration Oral030204 cardiovascular system & hematologyChronic liver diseaseSettore MED/04Biomarkers/analysisGastroenterologychemistry.chemical_compound0302 clinical medicine/dk/atira/pure/researchoutput/pubmedpublicationtype/D013485Liver Function TestsNon-alcoholic Fatty Liver DiseaseClinical endpointMedicine030212 general & internal medicine610 Medicine & healthChenodeoxycholic Acid/administration & dosageeducation.field_of_studyLiver Function TestResearch Support Non-U.S. Gov'tFatty liverObeticholic acidNASH OBETICHOLIC ACIDGeneral Medicine/dk/atira/pure/researchoutput/pubmedpublicationtype/D052061Middle AgedMulticenter Study/dk/atira/pure/researchoutput/pubmedpublicationtype/D016448Randomized Controlled TrialAdministrationFemale/dk/atira/pure/researchoutput/pubmedpublicationtype/D016449Administration Oral; Biomarkers; Biopsy; Chenodeoxycholic Acid; Double-Blind Method; Female; Humans; Liver Function Tests; Male; Middle Aged; Non-alcoholic Fatty Liver DiseaseHumanOralmedicine.medical_specialtyPopulationPlaceboChenodeoxycholic Acid03 medical and health sciencesResearch Support N.I.H. ExtramuralDouble-Blind MethodInternal medicineJournal ArticleHumans/dk/atira/pure/researchoutput/pubmedpublicationtype/D017428educationIntention-to-treat analysisbusiness.industryBiomarkerInterim analysismedicine.diseaseNon-alcoholic Fatty Liver Disease/drug therapychemistryHuman medicine/dk/atira/pure/researchoutput/pubmedpublicationtype/D016428businessBiomarkersAdministration; Oral; Biomarkers; Biopsy; Chenodeoxycholic Acid; Double-Blind Method; Female; Humans; Liver Function Tests; Male; Middle Aged; Non-alcoholic Fatty Liver Disease
researchProduct

Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci

2012

Background & Aims: A limited number of genetic risk factors have been reported in primary sclerosing cholangitis (PSC). To discover further genetic susceptibility factors for PSC, we followed up on,a second tier of single nucleotide polymorphisms (SNPs) from a genome-wide association study (GWAS). Methods: We analyzed 45 SNPs in 1221 PSC cases and 3508 controls. The association results from the replication analysis and the original GWAS (715 PSC cases and 2962 controls) were combined in a meta-analysis comprising 1936 PSC cases and 6470 controls. We performed an analysis of bile microbial community composition in 39 PSC patients by 16S rRNA sequencing. Results: Seventeen SNPs representing 1…

MaleLinkage disequilibriumendocrine system diseasesGenome-wide association studyPrimary biliary cirrhosisGenotypeBLOOD-GROUPBileChildPOPULATIONAged 80 and overGeneticseducation.field_of_studyPrimary sclerosing cholangitisdigestive oral and skin physiologyMiddle AgedFucosyltransferasesChild PreschoolDISEASESFemaleNeprilysinReceptors Tumor Necrosis Factor Member 14B-LYMPHOCYTEAdultRiskGenome-wide association studyAdolescentGenotypeSUSCEPTIBILITY LOCIFUT2Cholangitis SclerosingPopulationT-LYMPHOCYTE ATTENUATORSingle-nucleotide polymorphismBiologyPolymorphism Single Nucleotidedigestive systemArticlePrimary sclerosing cholangitisGenetic predispositionmedicineImmunogeneticsHumansGenetic Predisposition to DiseaseeducationMETAANALYSISAgedNON-SECRETOR STATUSHepatologymedicine.diseaseGENEdigestive system diseasesSingle nucleotide polymorphismGenetic LociImmunology
researchProduct

Genome-Wide Association Analysis in Primary Sclerosing Cholangitis

2010

Background & Aims We aimed to characterize the genetic susceptibility to primary sclerosing cholangitis (PSC) by means of a genome-wide association analysis of single nucleotide polymorphism (SNP) markers. Methods A total of 443,816 SNPs on the Affymetrix SNP Array 5.0 (Affymetrix, Santa Clara, CA) were genotyped in 285 Norwegian PSC patients and 298 healthy controls. Associations detected in this discovery panel were re-examined in independent case-control panels from Scandinavia (137 PSC cases and 368 controls), Belgium/The Netherlands (229 PSC cases and 735 controls), and Germany (400 cases and 1832 controls). Results The strongest associations were detected near HLA-B at chromosome 6p21…

LOCIMacrophage Stimulating 1 (Hepatocyte Growth Factor-Like)Genome-wide association studySUSCEPTIBILITYGene FrequencyHLA AntigensRisk FactorsHEPATOCELLULAR-CARCINOMAOdds RatioBileBiliary TractINCREASED RISKOligonucleotide Array Sequence AnalysisGastroenterologyMULTIPLE-SCLEROSISCROHNS-DISEASEEuropePhenotypeULCERATIVE-COLITISInflammation MediatorsSNP arrayCholangitis SclerosingSingle-nucleotide polymorphismLocus (genetics)Human leukocyte antigenBiologyPolymorphism Single NucleotideRisk AssessmentCell LinePrimary sclerosing cholangitisGlypicansGenetic predispositionmedicineHumansGenetic Predisposition to DiseaseGene SilencingACID RECEPTOR TGR5Genetic associationInflammationChi-Square DistributionHepatologyGene Expression ProfilingGlypican 6medicine.diseaseGENEG-Protein-Coupled Bile Acid Receptor 1Case-Control StudiesImmunologyColitis UlcerativeGenome-Wide Association StudyINFLAMMATORY-BOWEL-DISEASEGastroenterology
researchProduct

Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis.

2010

Autoimmune hepatitis (AIH) is a chronic liver disease associated with cirrhosis and liver failure. Corticosteroid therapy induces long-term remission but has many side effects. We compared the effects of budesonide (a steroid that is rapidly metabolized, with low systemic exposure) and prednisone, both in combination with azathioprine.We performed a 6-month, prospective, double-blind, randomized, active-controlled, multicenter, phase IIb trial of patients with AIH without evidence of cirrhosis who were given budesonide (3 mg, three times daily or twice daily) or prednisone (40 mg/d, tapered to 10 mg/d); patients also received azathioprine (1-2 mg/kg/d). Treatment was followed by a 6-month, …

BudesonideAdultMalemedicine.medical_specialtyCirrhosisAdolescentAzathioprineAutoimmune hepatitisChronic liver diseaseGastroenterology03 medical and health sciences0302 clinical medicineHLA-DR3 AntigenDouble-Blind MethodPrednisoneInternal medicineMedicineHumansProspective StudiesBudesonideChildAgedHepatitisIntention-to-treat analysisHepatologybusiness.industryGastroenterologyMiddle Agedmedicine.disease3. Good healthHepatitis AutoimmuneEndocrinology030220 oncology & carcinogenesisPrednisone030211 gastroenterology & hepatologyFemalebusinessmedicine.drugGastroenterology
researchProduct

Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci

2011

Primary sclerosing cholangitis (PSC) is a chronic bile duct disease affecting 2.4-7.5% of individuals with inflammatory bowel disease. We performed a genome-wide association analysis of 2,466,182 SNPs in 715 individuals with PSC and 2,962 controls, followed by replication in 1,025 PSC cases and 2,174 controls. We detected non-HLA associations at rs3197999 in MST1 and rs6720394 near BCL2L11 (combined P = 1.1 x 10(-16) and P = 4.1 x 10(-8), respectively).

Cholangitis SclerosingPATHOGENESISSingle-nucleotide polymorphismGenome-wide association studyHuman leukocyte antigenBiologyInflammatory bowel diseasePolymorphism Single Nucleotidedigestive systemArticlePrimary sclerosing cholangitisPathogenesisCohort StudiesHLA AntigensProto-Oncogene ProteinsGeneticsmedicineHumansGenetic Predisposition to DiseaseBOWEL-DISEASEGenetic associationBcl-2-Like Protein 11Bile ductHepatocyte Growth FactorGene Expression Profilingdigestive oral and skin physiologyMembrane Proteinsmedicine.diseasedigestive system diseasesmedicine.anatomical_structureGenetic LociImmunologyApoptosis Regulatory ProteinsGenome-Wide Association Study
researchProduct

Pregnancy in primary sclerosing cholangitis

2011

Background There is a paucity of data on fertility or pregnancy in patients with primary sclerosing cholangitis (PSC). Objective To assess fertility in PSC by comparing the number of children in a large cohort of PSC patients to healthy controls and to investigate the outcome of pregnancy, as well as the influence of pregnancy on the disease course. Design Case series. Setting Germany. Participants 229 PSC patients and 569 healthy controls were evaluated for the number of children. 17 patients with PSC and at least one pregnancy, or who received a diagnosis of PSC within 6 months after delivery, were included in the more detailed analysis. Main outcome measures Number of children per patien…

AdultCholagogues and Cholereticsmedicine.medical_specialtyTime FactorsAdolescentmedia_common.quotation_subjectCholangitis SclerosingFertilityAutoimmune hepatitisPrimary sclerosing cholangitisYoung AdultPregnancyRisk FactorsGermanyAzathioprinemedicineHumansYoung adultmedia_commonPregnancyFetusObstetricsbusiness.industryIncidenceIncidence (epidemiology)Ursodeoxycholic Aciddigestive oral and skin physiologyInfant NewbornPregnancy OutcomeGastroenterologymedicine.diseasedigestive system diseasesPregnancy ComplicationsImmunologyGestationFemalebusinessImmunosuppressive AgentsFollow-Up StudiesGut
researchProduct

1124 FERTILITY AND PREGNANCY IN PRIMARY SCLEROSING CHOLANGITIS

2010

medicine.medical_specialtyPregnancyHepatologybusiness.industryObstetricsmedia_common.quotation_subjectmedicineFertilitymedicine.diseasebusinessPrimary sclerosing cholangitismedia_commonJournal of Hepatology
researchProduct